Business
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
ALLO-715, an Allogeneic BCMA CAR T Candidate Dosed with an ALLO-647 Based Lymphodepletion Regimen, Continues to Demonstrate a Promising Clinical ProfileA
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"ALLO-715, an Allogeneic BCMA CAR T Candidate Dosed with an ALLO-647 Based Lymphodepletion Regimen, Continues to Demonstrate a Promising Clinical ProfileA Company Sponsored R&D Showcase on November 29, 2022 will Discuss Updated Data With Single Dose ALLO-715 and Future Development Plans SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will present updated data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory multiple myeloma, in a poster presentation at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, 2022 in New Orleans, LA. “UNIVERSAL is the first trial to demonstrate significant responses can be achieved with an allogeneic CAR T product candidate. We look forward to presenting updated clinical data with ALLO-715 as we aim to alleviate the barriers patients with multiple myeloma often face when seeking to access cell therapy,” said Rafael Amado, M.D., Executive Vice President of Research & Development of Allogene. The ASH abstract includes longer-term follow up from UNIVERSAL, including the updated safety experience and efficacy results from two expansion cohorts using lymphodepletion of FC (fludarabine, cyclophosphamide) and ALLO-647 at 39mg or 60mg and a single dose of ALLO-715 at 320M CAR positive cells. The Company will host an in-person and virtual Research & Development Showcase on Tuesday, November 29, 2022 in New York City. This event will include a discussion of updated data from the UNIVERSAL trial with single dose ALLO-715 and next steps for the program. The ASH abstracts are now available at www.hematology.org. Details on the ASH presentation are as follows: Allogene Poster Presentation Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster IAbstract #1972Title: Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple MyelomaPresenter: Sham Mailankody, MBBS, M.D.Session Date & Time: Saturday, December 10, 2022; 5:30 PM - 7:30 PM Central Time About Allogene TherapeuticsAllogene Therapeutics, with headquarters in S...